HOUSTON, TX – February 22, 2011 – Glycos Biotechnologies, Inc. (GlycosBio), an international biochemical company commercializing advanced biological processes that convert low-value feedstocks into high-value sustainable chemicals, today announced it has been granted the BioNexus Status from the Malaysian Government via Biotechnology Corporation (BiotechCorp), the national agency set up by the Malaysian government for the development of biotechnology in Malaysia.  This announcement marks another key milestone in GlycosBio’s expansion into Malaysia with the construction of the Company’s industrial biochemical plant and biotechnology research and development facility in Bio-XCell, a dedicated biotechnology park in Johor, Malaysia.

BioNexus Status is a recognition awarded by the Malaysian Government, through BiotechCorp, to qualified companies that participate in and undertake value-added biotechnology activities.  To date, 187 companies have been granted the BioNexus status and ten of these companies have United States shareholding.

“We are honored that BiotechCorp has granted GlycosBio with the esteemed designation of BioNexus Status and proud to join this elite group of companies,” said Richard Cilento, Chief Executive Officer of Glycos Biotechnologies.  “GlycosBio will gain a number of financial incentives and business development support services with this status further excelling our growth and expansion efforts in the Malaysian region.  The BioNexus status demonstrates the benefits of a collaborative effort between private enterprises and the strategic objectives of the Malaysian government. Having the support of BiotechCorp and working closely with their dedicated professionals has proven to be a key differentiator for GlycosBio and the emerging biochemical value chain we are supporting.”

GlycosBio was one of the first biochemical companies to partner with BiotechCorp in 2010 to construct a biochemical plant and biotechnology research and development facility in the Bio-XCell biotechnology ecosystem. Bio-XCell is Malaysia’s dedicated biotechnology park for industrial and healthcare biotechnology.  GlycosBio’s expansion plans are on schedule with the facilities construction and are expected to complete in 2012.  GlycosBio plans to focus much of its initial research and development efforts on creating isoprene to support Malaysia’s rubber industry.

“GlycosBio’s presence in Bio-XCell will not only provide Malaysia with human capital development and expanded investment opportunities but also support several of Malaysia’s economic objectives from providing palm oil and oleochemical producers more sustainable production methods to supporting the isoprene related industry which may include polymers such as rubber,” said Iskandar Mizal Mahmood, Chief Executive Officer, Malaysian Biotechnology Corporation.  “As one of the first companies to participate in the Bio-XCell ecosystem, GlycosBio will be a critical contributor to Malaysia’s near and long-term industrial and biotechnology goals.”

BioNexus Status companies enjoy a set of incentives contained within the BioNexus Bill of Guarantees.  BioNexus Status companies also receive continuous support and assistance from BiotechCorp on immigration related matters, IP advisory and regulatory services and employment related matters.  BiotechCorp also provides a wide range of capacity building programs covering a variety of subject matter to assist biotechnology entrepreneurs in managing their business locally and internationally.

About Glycos Biotechnologies, Inc.

Glycos Biotechnologies, Inc. (“GlycosBio”) is an international biochemical company commercializing advanced metabolic engineering and microbial strain processes that convert multiple low value feedstocks into a range of high value sustainable chemicals. By designing a portfolio of differentiated microorganisms, GlycosBio’s bioconversion technology produces a diverse set of chemicals, including substitutes for fossil fuel derived petrochemicals, meeting the growing global demand for clean, environmentally safe biochemicals.

GlycosBio is privately held and focused on biochemical commercialization and production with established global partnerships including relationships with petrochemical companies to secure low cost, non-petroleum based chemicals.  For more information, visit www.glycosbio.com.

About BiotechCorp

BiotechCorp is the lead development agency for the biotech industry in Malaysia and acts as a central contact point providing support, facilitation, and advisory services for life sciences companies in Malaysia. Since its establishment in 2005, BiotechCorp has played a key role in building the biotech business in Malaysia. To date, BiotechCorp has facilitated the development of 187 BioNexus-status companies in Malaysia, with total approved investment of close to RM 2 billion. BioNexus-status companies are international and Malaysian biotech companies that qualify for fiscal incentives, grants, and guarantees administered by BiotechCorp. For more information, visit www.biotechcorp.com/my.

About Bio-XCell

Bio-XCell is a biotechnology park and ecosystem for industrial and healthcare biotechnology, with a focus on manufacturing and R&D. Developed by Malaysian Bio-XCell Sdn Bhd, a joint venture company between BiotechCorp and UEM Land, the park is slanted to be the new regional biotech hub of Asia. Capitalising on value propositions of both its shareholders, Bio-XCell provides comprehensive infrastructure, services, incentives and benefits to drive the growth for the biotechnology sector.

Strategically located in Nusajaya, Iskandar Malaysia, the resource-rich state of Johor, Bio-XCell provides global connectivity through the network of five seaports and two international airports, all within 59kms. For information or leasing inquiries, log on to www.bio-xcell.com.

MEDIA CONTACT

Suzanne Tormollen
Atingo Public Relations
281-785-1280
suzanne@atingo.com

HOUSTON, TX – February 10, 2011 – Glycos Biotechnologies, Inc. (GlycosBio), an international biochemical company commercializing advanced metabolic engineering and microbial strain processes to convert low-value feedstocks into high-value sustainable chemicals, today announced the appointment of Gary Mossman, chemical industry veteran, to the Company’s Board of Directors.  Mossman’s experience spans both large and small molecular technology with more than 40 years of executive management and investment responsibility in private and public pharmaceutical and specialty chemical firms.

“GlycosBio is very pleased to welcome Gary to our Board of Directors,” said Richard Cilento, Chief Executive Officer of Glycos Biotechnologies.  “Gary’s range of expertise in chemicals, pharmaceuticals and manufacturing coupled with his business, technical and leadership background will play an integral role in GlycosBio’s efforts to continue developing innovative products and further advance the Company’s position as a leader in producing sustainable biochemicals.”

Mossman is currently Chief Operating Officer (COO) and Director of PLx Pharma, an emerging Pharma company and Chairman of Redline Industries, a metal fabricator.  In addition, he is a director of the Nassau Bay Economical Development Council and the CCISD Educational Foundation.   Previously, Mossman held the position of Executive Vice President and COO of Cambrex Corporation where he was responsible for global operations of this leading provider of API’s including Generics, Biotech and Pharma Development Services, Drug Delivery, and Diagnostic Products.  Mossman also served as Chief Executive Officer and Vice Chairman of Dixie Chemical Company, a top tier specialty chemical company.

“The majority of my professional career has been focused in specialty chemicals, biotechnology and biopharmaceuticals,” said Mossman. “GlycosBio is a smart company making incredible discoveries to help further the industry’s advancement toward biochemical independence and I’m excited to have the opportunity to extend my experience and knowledge to GlycosBio to help them continue to reach their business goals.”

Mossman joins current GlycosBio Board of Directors members including Walter Burnap, President and Chief Financial Officer of GlycosBio; Richard Cilento, Chief Executive Officer of GlycosBio; Steve Jurvetson, Managing Director, Draper Fisher Jurvetson; and Dan Watkins, Managing Director of DFJ Mercury.

About Glycos Biotechnologies, Inc.

Glycos Biotechnologies, Inc. (“GlycosBio”) is an international biochemical company commercializing advanced metabolic engineering and microbial strain processes that convert multiple low value feedstocks into a range of high value sustainable chemicals. By designing a portfolio of differentiated microorganisms, GlycosBio’s bioconversion technology produces a diverse set of chemicals, including substitutes for fossil fuel derived petrochemicals, meeting the growing global demand for clean, environmentally safe biochemicals.

GlycosBio is privately held and focused on biochemical commercialization and production with established global partnerships including relationships with petrochemical companies to secure low cost, non-petroleum based chemicals.  For more information, visit www.glycosbio.com.

MEDIA CONTACT

Suzanne Tormollen
Atingo Public Relations
281-785-1280
suzanne@atingo.com

Paul Campbell, Chief Science Officer for GlycosBio, will participate in a panel with other leading biochemical companies to explore the growing shift in the industry from biofuel to biochemical production.  Panelists will examine why companies may be choosing biochemicals over biofuels, the long-term sustainability and future of such a choice, and the potential synergies between these two strategies.

With more than 90 speakers confirmed, the 2^nd Annual Next Generation Bio-Based Chemicals Summit is quickly becoming a growing tradition for key industry players, leading developers, government representatives, ground breaking researchers, and renowned financiers to gather, discuss and foster cutting edge innovations for bio-based chemicals.

What: “Expanding from Fuels to Chemicals”

Who: Moderator

John Eustermann, Partner, Stoel Rivers, LLP

Panelists

Alan Berry, Director, Microbial Physiology and HTS, Novozymes, Inc.

Doug Cameron, Managing Director, Alberti Advisors, LLC

Paul Campbell, PhD., Chief Science Officer, Glycos Biotechnologies

Vonnie Estes, Vice President, Corporate Development, Codexis, Inc.

Joseph Kocal, Director of Renewable Research, UOP, a Division of Honeywell, Inc.

Where: Hilton San Diego Resort & Spa

When: Wednesday, February 16^th, 10:30am – 11:30am

For more information about the Next Generation Bio-Based Chemicals Summit, visit http://www.infocastinc.com/index.php/conference/436.

About Glycos Biotechnologies, Inc.

Glycos Biotechnologies, Inc. (“GlycosBio”) is an international biochemical company commercializing advanced metabolic engineering and microbial strain processes that convert multiple low value feedstocks into a range of high value sustainable chemicals. By designing a portfolio of differentiated microorganisms, GlycosBio’s bioconversion technology produces a diverse set of chemicals, including substitutes for fossil fuel derived petrochemicals, meeting the growing global demand for clean, environmentally safe biochemicals.

GlycosBio is privately held and focused on biochemical commercialization and production with established global partnerships including relationships with petrochemical companies to secure low cost, non-petroleum based chemicals.  For more information, visit www.glycosbio.com.

MEDIA CONTACT

Suzanne Tormollen
Atingo Public Relations
281-785-1280
suzanne@atingo.com

Executives from GlycosBio, lead by Chief Executive Officer, Richard Cilento, joined Malaysian dignitaries including the Deputy Prime Minister, Muhyiddin Yassin; Deputy Minister of Science, Technology and Innovation, Fadhilah Yusofi; the Chairman of Malaysian Bio-XCell, Iskandar Mizal Mahmood; and Chief Executive Officer of Malaysian Bio-XCell, Raja Ridzwa Aziz in an official Ceremony for the exchange of Agreements between Bio-XCell and GlycosBio.

GlycosBio announced in May its partnership with Malaysian Bio-XCell Sdn. Bhd. to build an industrial biochemical plant and a biotechnology research and development facility to be operational in 2012.  The company plans to focus much of its initial research and development efforts on creating isoprene to support Malaysia’s rubber industry.

“For Malaysia, isoprene is a strategic product because of the large domestic latex industry and where we plan to focus much of our R&D efforts,” said Richard Cilento, Chief Executive Officer of Glycos Biotechnologies.  “With construction underway, our long-term strategy includes further expansion in Malaysian and across Southeast Asia forming joint venture partnerships with existing petrochemical, oleochemical, and biofuel producers and to partner with end market players in the development of advanced biochemicals.  There are great opportunities in Malaysia for our microbial platform and sustainable chemical processes and we look forward to the future possibilities.”

“GlycosBio will play a significant role in strengthening our value chain for industrial bioprocess and biomanufacturing within the Bio-XCell ecosystem.  This partnership will enhance our significance as a regional biotech hub for industrial and healthcare biotechnology,” said Raja Ridzwa Aziz, Chief Executive Officer of Bio-XCell.

“GlycosBio will also open opportunities for our Malaysian small and medium biotechnology enterprises to participate in its supply chain, promoting specialized services and products for the industry,” Raja Ridzwa added.

In addition, Paul Campbell Chief Science Officer for GlycosBio, will participate in a panel with other leading biotechnology scientists at the BioMalaysia 2010 Conference.  The panelists will provide an overview of green chemicals and biomaterials that can be created from renewable resources in addition to the fermentative utilization of glycerol and fatty acids for the production of bulk chemicals.  The panel presentation will take place Wednesday, November 3^rd at 2:20pm.

“GlycosBio has engineered a series of metabolic pathways that can produce nearly a dozen chemical intermediaries including ethanol, succinic acid, propanediols, and lactic acid from a variety of non food-based feedstocks including glycerol, cellulosic sugar, plant oils, algae and fatty acids,” said Campbell.  “Given the reach and flexibility of our platform, we can easily adapt and work with a market’s specific  need to create a variety of high value chemicals.  For this reason, we continue to be very excited about our work in Malaysia and are honored to be part of such a distinguished group of industry experts at BioMalaysia 2010.”

The BioMalaysia Conference and Exhibition is Malaysia’s largest international biotechnology conference held annually in Kuala Lumpur attracting participation from more than 150 companies.  Visitors will gain insights on the latest biotechnology business, research and development, and innovation in the areas of agriculture, animal and plant breeding, equipment and supplies, food and nutrition, nanotechnology, environment, chemicals and services, natural resources and Commodities/Bio Diversity and pharmaceuticals.

For attendees of BioMalaysia 2010, more information about GlycosBio and its work in Malaysia can be obtained from the Bio-XCell booth, #115.  For those not attending the conference, please visit www.glycosbio.com.  For more information about the BioMalaysia 2010 Conference, please visit http://www.biomalaysia.com.my/.

About Glycos Biotechnologies

Glycos Biotechnologies, Inc. (GlycosBio) is an emerging biochemical company pioneering the metabolic engineering of microbial strains to consume multiple non food-based, low value feedstocks for the production of sustainable chemicals and advanced ethanol.  By designing differentiated microorganisms, GlycosBio’s bioconversion technology lowers production costs and provides a non food energy balance savings to the chemical and biofuel industries.  GlycosBio is privately held with established global relationships focused on product commercialization.  For more information, visit www.glycosbio.com.

Media Contact:

Suzanne Tormollen
Atingo Public Relations
(281) 785-1280
suzanne@atingo.com

“GlycosBio chose to join the CBiRC because the Engineering Research Center’s vision and goals are in direct alignment with why we founded GlycosBio, to find a better way to make biochemicals,” said Paul Campbell, Chief Science Officer for Glycos Biotechnologies.  “By leveraging biotechnology processes, GlycosBio has created a microbial platform proven to produce higher value biochemicals and biofuels from lower value, underutilized feedstocks.   By optimizing the biochemical production of chemicals and microbial strains the cost of chemical production can be dramatically reduced while at the same time the diversity of chemicals can be greatly enhanced.  We believe that by supporting the CBiRC’s efforts, we can reach sustainability within the chemical industry and we are excited to be part of this organization.”

Launched in 2008, the CBiRC bases its engineering platform on three interconnected segments including enzyme and microbial engineering, chemical catalysis and catalysis engineering, and testbeds and life cycle analysis.  The CBiRC’s biocatalysis efforts are focused on the fatty acid or polyketide biosynthesis pathways with a goal of enhancing microbial production through targeted engineering.  According to the CBiRC, combining biocatalysis with chemical catalysis opens the door to developing an array of feedstock chemicals that will form the basis for founding a biorenwable chemicals industry.

The CBiRC is based at Iowa State University in partnership with Rice University, the University of California at Irvine, the University of Mexico, the University of Virginia, and the University of Wisconsin at Madison.  Fritz Haber Institute of the Max Planck Society in Germany and the Technical University of Denmark will contribute additional expertise and international connections.

For more information about the NSF Engineering Research Center for Biorenewable Chemicals, please visit www.cbirc.iastate.edu.

About Glycos Biotechnologies, Inc.

Glycos Biotechnologies, Inc. (GlycosBio) is an emerging biochemical company pioneering the metabolic engineering of microbial strains to consume multiple non food-based, low value feedstocks for the production of sustainable chemicals and advanced ethanol.  By designing differentiated microorganisms, GlycosBio’s bioconversion technology lowers production cost and provides a non-food energy balance savings to the chemical and biofuel industries.  GlycosBio is privately held with established global relationships focused on product commercialization.  For more information, visit www.glycosbio.com.

Media Contact:

Suzanne Tormollen
Atingo Public Relations
(281) 785-1280
suzanne@atingo.com

HOUSTON, TX – September 22, 2010 – Glycos Biotechnologies, Inc. (GlycosBio), an emerging biochemical company pioneering metabolic engineering and microbiology innovations for the production of sustainable biochemicals, today announced the addition of Rob Toker to the management team as Vice President of Partnerships and Market Research.  In his new role at GlycosBio, Toker will be responsible for the company’s overall partnership strategy and the related international market research required to successfully deploy GlycosBio’s technology worldwide.  Toker will also be focused on feedstock and commodity market analysis, negotiation and contracting.

“Rob brings a tremendous amount of industry and business expertise to GlycosBio,” said Rich Cilento, Chief Executive Officer for Glycos Biotechnologies.  “His in-depth knowledge of the renewable energy markets and biotechnology, not just in the U.S. but also abroad, will have a significant impact on the company’s go-to-market planning, product development and operational strategies.  Additionally, Rob will help the company seek out new business opportunities to expand and bring GlycosBio’s microbial platform to producers worldwide.  We’re excited to have Rob join the team.”

Prior to joining GlycosBio, Toker was Senior Vice President with Sindicatum Carbon Capital (SCC), a London – Singapore based clean energy developer and investment firm backed by Citigroup Alternative Investment and Black River (Cargill). While at SCC, Rob had a broad range of responsibilities working closely with project partners and hosts from origination, planning, financial and strategic analysis through structuring and financial close to ensure appropriate technology was integrated efficiently and deployed on time and on budget.  Before joining SCC, Toker was Head of Trade and Investment in Houston for UK Trade & Investment.  In addition to leading the regional team, Toker led the Houston-based International Energy Team and the Miami-based Trade and Investment team including the Latin American and Caribbean Market Intelligence Unit.  While at UK Trade & Investment, Toker was also responsible for the conceptualization and execution of the industrial biotechnology market strategy for the trade and investment network which systematically linked bio-energy research and development strengths in the United Kingdom with those in the Southern U.S. and Latin America. These activities linked life sciences, energy and finance expertise producing several commercially financeable, and economically viable renewable energy projects.  Toker started his career at the United Nations in New York.

“GlycosBio is at the forefront of the industry with a platform that offers a transformative shift in the way producers develop, manage and deliver biochemicals and biofuels,” said Toker.  “The breadth and reach of GlycosBio’s microbial platform offers producers worldwide the opportunity to expand their product portfolio and increase their product yields, ultimately enabling them to succeed and gain competitive differentiation.  I’m happy to be able to join GlycosBio at such a momentous time and look forward to helping the team continue its’ success.”

In addition to his resume credentials, Toker is also active in the energy investment community sitting on The Rice Alliance for Entrepreneurship and Technology advisory board; the University of Texas System Technology Transfer advisory board; the Greater Houston Partnership (GHP) Carbon Trading Task Force; and the Houston Technology Center (HTC) Energy Steering Committee. Toker is also a frequent presenter and occasional author.  His published works include a 2008 Harvard Business Review (HBR) article “Start Thinking about Carbon Assets – Now” and a 2009 HBR article “Can Technology Really Save us from Climate Change”.

About Glycos Biotechnologies, Inc.
Glycos Biotechnologies, Inc. (GlycosBio) is an emerging biochemical company pioneering the metabolic engineering of microbial strains to consume multiple non food-based, low value feedstocks for the production of sustainable chemicals and advanced ethanol.  By designing differentiated microorganisms, GlycosBio’s bioconversion technology lowers production cost and provides a non-food energy balance savings to the chemical and biofuel industries.  GlycosBio is privately held with established global relationships focused on product commercialization.  For more information, visit www.glycosbio.com.

Media Contact:

Suzanne Tormollen
Atingo Public Relations
(281) 785-1280
suzanne@atingo.com

HOUSTON, TX – September 15, 2010 – Glycos Biotechnologies, Inc. (GlycosBio), an emerging biochemical company pioneering metabolic engineering and microbiology innovations for the production of sustainable biochemicals, today announced it has created the first ever microbial platform for the efficient synthesis of biofuels and biochemicals from fatty acids.  This revolutionary advancement builds on GlycosBio’s microorganism platform and further diversifies the set of feedstocks and co-products the company offers enabling greater cost savings and product flexibility for producers.  This research was done in collaboration with GlycosBio’s Scientific Advisory Board Chairman Prof. Ramon Gonzalez, Ph.D, P.E. and his group at Rice University.  The results were recently published in the latest edition of Applied and Environmental Microbiology.

To-date cellulosic sugars from edible crops such as sugarcane, sugar beet, corn and sorghum have been used as the primary feedstock in the biological production of renewable fuels and chemicals.  Concern over the sustainability of cellulosic sugars for biofuel and biochemical production has caused the industry to look for alternative feedstock sources.  While nonedible cellulosic sugars have been proposed as an alternative, the availability of fatty acid-rich feedstocks and recent progress in the development of oil-accumulating organisms have made fatty acids an attractive option.

“Until now, microbial platforms to enable the biological production of fuels and chemicals from fatty acids have been nearly non-existent,” said Paul Campbell, Ph.D, Chief Science Officer for Glycos Biotechnologies.  “Through our research, we were able to prove the effectiveness of fatty acids to produce higher value chemicals and at very high yields with an empirical ethanol yield double that which is usually achieved with sugars.  These results demonstrate that fatty acids can be a great alternative to cellulosic sugars.”

By leveraging GlycosBio’s unique microbial conversion process, researchers were able to metabolically engineer native and heterologous fermentative pathways to function in E. coli under aerobic conditions.  This process created the industry’s first respiro-fermentative metabolic mode for the efficient catabolism of fatty acids and the synthesis of fuels and chemicals in E. coli.   Based on this discovery, the team of researchers was able to successfully synthesize biofuels including ethanol and butanol, and biochemicals including acetate, acetone, isopropanol, succinate and propionate from fatty acids.  Like ethanol, all of these chemicals show excellent yield advantages over the comparable sugar-based fermentation processes.

“At GlycosBio, we’ve been able to uniquely optimize the biochemical production of fuels and chemicals from microbial strains enabling a very flexible platform that can support a wide range of industrial and agricultural feedstocks,” said Walter Burnap, President and Chief Financial Officer for Glycos Biotechnologies.  “Edible oil-rich crops such as rapeseed, sunflower, soybean, and palm are widely available and non-edible fatty acid-rich crops along with industrial by-products are receiving more attention as longer-term alternatives. With this research complete, the industry can begin to realize the advantage of and choose a fatty acid approach to biofuel and biochemical production.  For GlycosBio, this research further supports our ability and opportunity to work with oleochemical and biodiesel producers who generate glycerol and fatty acid wastes.”

For more information about the research and its findings, please visit http://aem.asm.org/cgi/content/abstract/76/15/5067 to access the published report entitled, “Engineered Respiro-Fermentative Metabolism for the Production of Biofuels and Biochemicals from Fatty Acid-Rich Feedstocks”.

About Glycos Biotechnologies, Inc.

Glycos Biotechnologies, Inc. (GlycosBio) is an emerging biochemical company pioneering the metabolic engineering of microbial strains to consume multiple non sugar-based, low value feedstocks for the production of sustainable chemicals and advanced ethanol.  By designing differentiated microorganisms, GlycosBio’s bioconversion technology lowers production cost and provides a non-food energy balance savings to the chemical and biofuel industries.  GlycosBio is privately held with established global relationships focused on product commercialization.  For more information, visit www.glycosbio.com.

Paul Campbell, Chief Science Officer for GlycosBio, will participate in a panel with other leading biotechnology scientists discussing the advances in fermentation and bioprocesses. Campbell will present about GlycosBio’s microbial technology and its unique ability to convert non-sugar carbon sources such as glycerin into high value chemicals including technical grade alcohols, acetone, isoprene, succinc acid, diols and lactic acid.

BIO’s World Congress on Industrial Biotechnology and Bioprocessing is a unique interdisciplinary forum presenting the latest developments in biotechnology for biofuels, renewable chemicals, biobased materials, and biotech-based manufacturing and processing.  In its seventh year, the event will explore ways that public policy can help drive innovation and the commercialization of industrial biotechnology and bioprocessing.

What: “Advanced Biofuel Technologies: Advances in Fermentation”

Who: Paul Campbell, PhD., Chief Science Officer, Glycos Biotechnologies

Jan de Bont, Manager, Research & Development, Royal Nedalco

Kevin Gray, Senior Vice President and Chief Technology Officer, Qteros

Where: Gaylord Resort & National Convention Center, Washington, DC.

When: Tuesday, June 29^th, 9:00am – 10:30am

For more information about the 2010 World Congress on Industrial Biotechnology and Bioprocessing, visit http://www.bio.org/worldcongress.

About Glycos Biotechnologies, Inc.

Glycos Biotechnologies, Inc. (GlycosBio) is an emerging biochemical company pioneering the metabolic engineering of microbial strains to consume multiple non sugar-based, low value feedstocks for the production of sustainable chemicals and advanced ethanol.  By designing differentiated microorganisms, GlycosBio’s bioconversion technology lowers production cost and provides a non food energy balance savings to the chemical and biofuel industries.  GlycosBio is privately held with established global relationships focused on product commercialization.  For more information, visit www.glycosbio.com.

The William W. Akers Assistant Professor in the Departments of Chemical and Biomolecular Engineering and Bioengineering at Rice University in Houston, Gonzalez and his team of researchers identified the metabolic processes and conditions that allow a known strain of E. coli to convert glycerine, the major byproduct of biodiesel production, into ethanol.

By discovering innovative pathways that mediate glycerol fermentation in E. coli, Gonzalez was able to develop new technologies for converting glycerol into high-value chemicals. Through this research and discovery, Gonzalez and his team designed strains of E. coli that could produce a range of products from biofuels, ethanol, hydrogen and organic acids.

GlycosBio was founded based on Gonzalez’s discovery.  The company is using this technology innovation to enable petrochemical, palm oil, oleochemical and biofuel producers to convert by-products including glycerol and free fatty acids into higher-value green chemicals.  By not following the typical sugars-based fermentation research, GlycosBio offers the industry an alternative approach to traditional corn or sugar-based biofuel and chemical production.

About Glycos Biotechnologies, Inc.

Glycos Biotechnologies, Inc. (GlycosBio) is an emerging biochemical company pioneering the metabolic engineering of microbial strains to consume multiple non sugar-based, low value feedstocks for the production of sustainable chemicals and advanced ethanol.  By designing differentiated microorganisms, GlycosBio’s bioconversion technology lowers production cost and provides a non-food energy balance savings to the chemical and biofuel industries.  GlycosBio is privately held with established global relationships focused on product commercialization.  For more information, visit www.glycosbio.com.

HOUSTON, TX – May 5, 2010 – Glycos Biotechnologies, Inc. (GlycosBio), an emerging biochemical company pioneering metabolic engineering and microbiology innovations for the production of sustainable biochemicals, today announced it is presenting at the BIO International Convention taking place May 3^rd – 6^th in Chicago, IL.  GlycosBio’s Chief Executive Officer, Richard Cilento, will participate in the Malaysian Biotechnology Corporation (BioTechCorp) Business Roundtable addressing Malaysia’s biotech environment, work underway, and how the industry and government are collaborating to bring products to the marketplace.

As the lead development agency for the biotech industry in Malaysia and central contact point providing support, facilitation and advisory services for biotech and life sciences companies in Malaysia, BioTechCorp is bringing together Malaysian dignitaries and biotechnology executives to discuss and develop a further understanding of the business and development opportunities in Malaysia for biotechnology commercialization.

What: “Accelerating Commercialization in Biotechnology”

Who: Richard Cilento, Glycos Biotechnologies, Chief Executive Officer

Dato’ Iskandar Mizal Mahmood, BioTechCorp, Chief Executive Officer

Dr. Shermal Perrera, Siogen  Biotech, Managing Director

Madhukumar MK, Stempeutics Research, Country Manager

Meiert J. Grootes, Panadoro Group, Chief Executive Officer

Where: Room CC 11B, Hyatt McCormick Regency Hotel, Chicago, IL

When: Wednesday, May 5^th, 11:00am – 12:15pm

About Glycos Biotechnologies, Inc.

Glycos Biotechnologies, Inc. (GlycosBio) is an emerging biochemical company pioneering the metabolic engineering of microbial strains to consume multiple non sugar-based, low value feedstocks for the production of sustainable chemicals and advanced ethanol.  By designing differentiated microorganisms, GlycosBio’s bioconversion technology lowers production cost and provides a non food energy balance savings to the chemical and biofuel industries.  GlycosBio is privately held with established global relationships focused on product commercialization.  For more information, visit www.glycosbio.com.

MEDIA CONTACT
Suzanne Tormollen
Atingo Public Relations
281-785-1280suzanne@atingo.com